Search clinical trials for: dacomitinib intravenous

Total 6409 results

Pfizer

Completed

A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers

Healthy Volunteers

United Kingdom
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Shanghai Chest Hospital

Recruiting

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Non-small Cell Lung Cancer Metastatic | EGF-R Positive Non-Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Not yet recruiting

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
David Piccioni, M.D., Ph.D
Pfizer

Terminated

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Brain Cancer

United States
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Pfizer

Recruiting

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Lung Cancer

Malaysia
Pfizer

Completed

Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers

Healthy

China
Pfizer

Completed

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Healthy | Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction

United States
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Pfizer

Completed

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

Healthy Volunteers

Belgium
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Pfizer

Completed

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis (HER-Uro01)

Carcinoma, Squamous Cell | Penile Neoplasms

Italy
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Skin Squamous Cell Cancer

Italy
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Pfizer

Completed

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States
National Cancer Centre, Singapore
Singapore Translational Cancer Consortium; Genome Institute of Singapore; Cancer...

Recruiting

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Advanced Solid Tumours

Singapore
Samsung Medical Center

Recruiting

Central Nervous System(CNS) Efficacy of Dacomitinib

Non Small Cell Lung Cancer | Brain Metastases

Korea, Republic of
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Pfizer

Not yet recruiting

A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

Carcinoma, Non-Small-Cell Lung
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Lung Cancer | Lung Cancer Metastatic | EGFR Gene Mutation

United States
British Columbia Cancer Agency

Approved for marketing

18F-FDG PET Imaging in Cardiac Sarcoidosis

Cardiac Sarcoidosis

Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Metastatic Non-small Cell Lung Cancer

United States
Pfizer

Completed

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Metastatic Non Small Cell Lung Cancer

India
The Netherlands Cancer Institute
Pfizer

Unknown

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (M13DAP)

Colorectal Cancer

Netherlands
Pfizer

Completed

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Neoplasm Metastasis | Carcinoma, Non-Small Cell

United States, France, Spain
Fondazione Ricerca Traslazionale

Recruiting

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)

NSCLC

Italy
Lightpoint Medical Limited
Semmelweis University

Withdrawn

Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery (CLIO)

Gastric Cancer | Pancreatic Cancer | Bile Duct Cancer | Duodenal Cancer

Hungary
Central European Cooperative Oncology Group

Terminated

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Austria
Yuzuncu Yıl University

Unknown

Powder Topical Rifampicin on Reducing Infections After Neural Tube Defect Surgery in Infants

Postoperative Infection Rates

Turkey
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Royan Institute

Completed

Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)

Chronic Kidney Disease

Iran, Islamic Republic of
Mongi Slim Hospital

Completed

Prevention of Bleeding in Total Joint Replacement: Combined Route Administration of Tranexamic Acid

Arthroplasty, Replacement, Knee | Blood Transfusion | Arthroplasty, Replacement, Hip | Tranexamic Acid

Tunisia
University of Minnesota

Completed

Enhanced Nutrition for Preterm Infants

Preterm Birth

United States
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Pfizer

Completed

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Neoplasm

United States, Spain, Canada, Italy, United Kingdom
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
MicuRx
Worldwide Clinical Trials

Completed

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Safety
Asklepion Pharmaceuticals, LLC

Completed

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

Atrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal Defect

United States
Eli Lilly and Company

Completed

A Study of LY3016859 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom
Chaitanya Hospital, Pune

Unknown

Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy (BMMNC)

Muscular Dystrophy | Duchenne Muscular Dystrophy

India
Andalusian Initiative for Advanced Therapies -...
Iniciativa Andaluza en Terapias Avanzadas

Completed

A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral

Amyotrophic Lateral Sclerosis

Spain
UCB Celltech
Parexel

Completed

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Healthy

United Kingdom
GlaxoSmithKline

Completed

SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Lung Injury, Acute

United States
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia

Search clinical trials for: dacomitinib intravenous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations